Navidea Biopharmaceuticals (NAVB) Short Interest Ratio & Short Volume $0.0007 0.00 (0.00%) As of 06/3/2025 03:51 PM Eastern Add Compare Share Share Short Interest Stock AnalysisChartCompetitorsOptions ChainSEC FilingsShort InterestTrendsBuy This Stock Navidea Biopharmaceuticals Short Interest DataNavidea Biopharmaceuticals (NAVB) has a short interest of 400 shares. This marks a 33.33% increase in short interest from the previous month. The short interest ratio (days to cover) is 0.4, indicating that it would take 0.4 days of the average trading volume of 9,528 shares to cover all short positions.Current Short Interest400 sharesPrevious Short Interest300 sharesChange Vs. Previous Month+33.33%Dollar Volume Sold Short$0.28Short Interest Ratio0.4 Days to CoverLast Record DateMay 15, 2025Outstanding Shares100,084,000 sharesPercentage of Shares Shorted0.00%Today's Trading Volume3,055 sharesAverage Trading Volume9,528 sharesToday's Volume Vs. Average32% Short Selling Navidea Biopharmaceuticals? Sign up to receive the latest short interest report for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartNAVB Short Interest Over TimeNAVB Days to Cover Over TimeNAVB Percentage of Float Shorted Over Time Navidea Biopharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/2025400 shares $0.28 +33.3%N/A0.4 $0.00 4/30/2025300 shares $0.18 -25.0%N/A0 $0.00 4/15/2025400 shares $0.24 No ChangeN/A0.1 $0.00 3/14/2025400 shares $0.04 No ChangeN/A0.2 $0.00 2/14/2025400 shares $0.28 No ChangeN/A0 $0.00 1/31/2025400 shares $0.40 No ChangeN/A0.1 $0.00 1/15/2025400 shares $0.04 No ChangeN/A0 $0.00 6/15/2023570,200 shares $51,318.00 -35.3%4.5%0.1 $0.09 5/31/2023881,100 shares $81,061.20 +1,888.9%3.7%0.4 $0.09 5/15/202344,300 shares $0.00 -92.5%0.2%0.1 $0.00 Get the Latest News and Ratings for NAVB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Navidea Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 4/30/2023592,800 shares $0.00 +28.7%2.7%4.1 $0.00 4/15/2023460,700 shares $133,049.70 -7.0%2.1%3.8 $0.29 3/31/2023495,500 shares $0.00 +6.3%2.3%3.7 $0.00 3/15/2023466,100 shares $0.00 +4.2%2.2%3.1 $0.00 2/28/2023447,300 shares $0.00 +2.0%2.1%3 $0.00 2/15/2023438,500 shares $0.00 +38.2%2.1%2.9 $0.00 1/31/2023317,300 shares $0.00 +660.9%1.5%2.3 $0.00 1/15/202341,700 shares $0.00 +118.3%0.2%0.4 $0.00 12/30/202219,100 shares $0.00 -83.7%0.1%0.2 $0.00 12/15/2022117,200 shares $0.00 -12.5%0.5%1.7 $0.00 11/30/2022133,900 shares $0.00 +27.5%0.6%1.3 $0.00 11/15/2022105,000 shares $0.00 -8.2%0.5%0.8 $0.00 10/31/2022114,400 shares $0.00 -50.2%0.5%0.7 $0.00 10/15/2022229,900 shares $0.00 -50.7%1.1%1.4 $0.00 9/30/2022466,700 shares $0.00 +20.2%2.2%3 $0.00 9/15/2022388,300 shares $0.00 +60.3%1.8%2.6 $0.00 8/31/2022242,300 shares $0.00 +319.9%1.1%2.3 $0.00 8/15/202257,700 shares $0.00 -2.9%0.3%0.9 $0.00 7/31/202259,400 shares $0.00 -38.1%0.3%1.4 $0.00 7/15/202296,000 shares $0.00 -5.0%0.4%1.9 $0.00 6/30/2022101,000 shares $0.00 +45.3%0.5%0.3 $0.00 6/15/202269,500 shares $0.00 -16.3%N/A0.2 $0.00 5/31/202283,000 shares $0.00 +2.1%0.4%0.2 $0.00 5/15/202281,300 shares $0.00 -63.6%0.4%0.2 $0.00 4/30/2022223,300 shares $0.00 +121.5%1.0%0.6 $0.00 4/15/2022100,800 shares $0.00 -1.0%0.5%0.3 $0.00 3/31/2022101,800 shares $0.00 -33.4%0.5%1.6 $0.00 3/15/2022152,800 shares $0.00 -15.9%0.7%2.1 $0.00 2/28/2022181,600 shares $0.00 -7.6%0.8%2.2 $0.00 2/15/2022196,500 shares $0.00 -12.4%0.9%2.3 $0.00The Social Security Changes No One’s Talking About (Ad)While most Americans worry about their next Social Security check... something far bigger is happening behind the scenes. An AI plan — authorized by Executive Order — is about to rewrite how the SSA operates.To see the full playbook and how it could impact everyone, click here. 1/31/2022224,400 shares $0.00 -1.4%1.0%2.4 $0.00 1/15/2022227,500 shares $0.00 +1.9%1.1%3.3 $0.00 12/31/2021223,200 shares $0.00 +63.9%1.0%3.1 $0.00 12/15/2021136,200 shares $0.00 -7.1%0.6%2.1 $0.00 11/30/2021146,600 shares $0.00 +4.1%0.7%2.3 $0.00 11/15/2021140,900 shares $0.00 -10.8%0.6%2.4 $0.00 10/29/2021157,900 shares $0.00 -9.3%0.7%2.9 $0.00 10/15/2021174,100 shares $0.00 -7.0%0.8%4 $0.00 9/30/2021187,200 shares $0.00 +13.8%0.9%3 $0.00 9/15/2021164,500 shares $0.00 -5.4%0.8%2.5 $0.00 8/31/2021173,800 shares $0.00 +9.3%0.8%2.4 $0.00 8/13/2021159,000 shares $0.00 -17.0%0.7%1.4 $0.00 7/30/2021191,500 shares $0.00 -4.3%0.9%1.5 $0.00 7/15/2021200,000 shares $0.00 -1.6%1.0%1.4 $0.00 6/30/2021203,200 shares $0.00 +12.3%1.0%1.4 $0.00 6/15/2021181,000 shares $0.00 +30.2%0.9%0.9 $0.00 5/28/2021139,000 shares $0.00 -23.4%0.7%0.7 $0.00 5/14/2021181,500 shares $0.00 +5.5%N/A0.8 $0.00 4/30/2021172,000 shares $0.00 -7.2%N/A0.6 $0.00 4/15/2021185,300 shares $290,921.00 -15.5%N/A0.5 $1.57 3/31/2021219,400 shares $355,428.00 +49.3%N/A0.6 $1.62 3/15/2021147,000 shares $255,780.00 -22.3%N/A0.4 $1.74 2/26/2021189,200 shares $389,752.00 +13.8%N/A0.6 $2.06 2/12/2021166,200 shares $402,204.00 -33.0%N/A0.5 $2.42 1/29/2021248,100 shares $615,288.00 -8.4%N/A0.6 $2.48 1/15/2021270,800 shares $785,320.00 -2.9%N/A0.9 $2.90 12/31/2020279,000 shares $558,000.00 -1.6%N/A1.1 $2.00 12/15/2020283,500 shares $532,980.00 +9.0%N/A1.2 $1.88 11/30/2020260,000 shares $624,000.00 +32.9%N/A1.1 $2.40 11/15/2020195,600 shares $539,856.00 +3.4%N/A0.8 $2.76 10/30/2020189,100 shares $457,622.00 -3.3%N/A1.1 $2.42 10/15/2020195,600 shares $535,944.00 -11.1%N/A0.8 $2.74 9/30/2020220,100 shares $594,270.00 +11.4%N/A0.7 $2.70 9/15/2020197,500 shares $582,625.00 -12.7%1.1%0.6 $2.95 8/31/2020226,100 shares $671,517.00 +5.0%1.3%0.5 $2.97 8/14/2020215,300 shares $704,031.00 -5.2%1.3%0.3 $3.27 7/31/2020227,000 shares $1.09 million -37.0%1.3%0.1 $4.78 7/15/2020360,500 shares $1.44 million -15.6%2.1%0.2 $3.99 6/30/2020427,100 shares $1.63 million -20.5%2.7%0.2 $3.81 6/15/2020537,300 shares $1.61 million -61.9%3.4%0.3 $2.99 NAVB Short Interest - Frequently Asked Questions What is Navidea Biopharmaceuticals' current short interest? Short interest is the volume of Navidea Biopharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of May 15th, traders have sold 400 shares of NAVB short. Learn More on Navidea Biopharmaceuticals' current short interest. Is Navidea Biopharmaceuticals' short interest increasing or decreasing? Navidea Biopharmaceuticals saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 400 shares, an increase of 33.3% from the previous total of 300 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Navidea Biopharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Navidea Biopharmaceuticals: TC Biopharm (Holdings) Plc (176.43%), Vincerx Pharma, Inc. (0.04%), NuCana plc (57.22%), Aditxt, Inc. (2.14%), Smart for Life, Inc. (0.01%), Scopus BioPharma Inc. (0.02%), Aridis Pharmaceuticals, Inc. (0.00%), eFFECTOR Therapeutics, Inc. (0.12%), Evelo Biosciences, Inc. (0.04%), Genocea Biosciences, Inc. (0.33%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($29.20 billion), Strategy Incorporated ($10.88 billion), iShares 20+ Year Treasury Bond ETF ($10.04 billion), Capital One Financial Co. ($5.51 billion), Charter Communications, Inc. ($5.00 billion), Super Micro Computer, Inc. ($4.43 billion), Apollo Global Management, Inc. ($4.02 billion), Hims & Hers Health, Inc. ($3.65 billion), VanEck Semiconductor ETF ($3.27 billion), and Coinbase Global, Inc. ($3.10 billion). View all of the most shorted stocks. What does it mean to sell short Navidea Biopharmaceuticals stock? Short selling NAVB is an investing strategy that aims to generate trading profit from Navidea Biopharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Navidea Biopharmaceuticals? A short squeeze for Navidea Biopharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of NAVB, which in turn drives the price of the stock up even further. How often is Navidea Biopharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including NAVB, twice per month. The most recent reporting period available is May, 15 2025. More Short Interest Resources from MarketBeat Related Companies TCBP Short Interest VINC Short Interest NCNA Short Interest ADTX Short Interest SMFL Short Interest SCPS Short Interest ARDS Short Interest EFTR Short Interest EVLO Short Interest GNCAQ Short Interest Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NYSE:NAVB) was last updated on 6/5/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredJunior Explorer Taps Into TSMC’s $165 Billion Chip CorridorThe chip war is moving underground. As the U.S. ramps up semiconductor production to outpace China, an unex...Capital Trends | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Navidea Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Navidea Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
